FEMY Key Statistics, Chart & Performance
The current stock price of FEMY is 0.5905 USD. In the past month the price decreased by -28.56%. In the past year, price decreased by -45.32%.
FEMY Latest News, Press Relases and Analysis
FEMY Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.29 | 219.41B | ||
| ISRG | INTUITIVE SURGICAL INC | 67.95 | 207.41B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.35 | 145.84B | ||
| SYK | STRYKER CORP | 27.88 | 140.43B | ||
| BDX | BECTON DICKINSON AND CO | 14.23 | 58.56B | ||
| IDXX | IDEXX LABORATORIES INC | 56.49 | 56.88B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.91 | 49.08B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 19.21 | 40.16B | ||
| RMD | RESMED INC | 25.35 | 36.63B | ||
| DXCM | DEXCOM INC | 36.79 | 26.69B | ||
| PODD | INSULET CORP | 64.09 | 20.60B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.63 | 18.64B |
Related stock screener links
About FEMY
Company Profile
Femasys, Inc. is a biomedical company, which engages in the development of novel solutions for reproductive healthcare. The company is headquartered in Suwanee, Georgia and currently employs 69 full-time employees. The company went IPO on 2021-06-18. The firm is focused on addressing the unmet needs of women worldwide with a broad portfolio of in-office, accessible, and therapeutic and diagnostic solutions. The firm has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable blended biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. The company also developed FemCerv, which is an endocervical tissue sampler for cervical cancer diagnosis; FemVue, which is a companion diagnostic for fallopian tube assessment; FemCath, which is an intrauterine catheter, and FemChec.
Company Info
FEMASYS INC
3950 Johns Creek Court, Suite 100
Suwanee GEORGIA US
CEO: Kathy Lee-Sepsick
Employees: 69
Phone: 17705003910
FEMASYS INC / FEMY FAQ
What does FEMASYS INC do?
Femasys, Inc. is a biomedical company, which engages in the development of novel solutions for reproductive healthcare. The company is headquartered in Suwanee, Georgia and currently employs 69 full-time employees. The company went IPO on 2021-06-18. The firm is focused on addressing the unmet needs of women worldwide with a broad portfolio of in-office, accessible, and therapeutic and diagnostic solutions. The firm has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable blended biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. The company also developed FemCerv, which is an endocervical tissue sampler for cervical cancer diagnosis; FemVue, which is a companion diagnostic for fallopian tube assessment; FemCath, which is an intrauterine catheter, and FemChec.
What is the stock price of FEMASYS INC today?
The current stock price of FEMY is 0.5905 USD. The price decreased by -5.46% in the last trading session.
What is the dividend status of FEMASYS INC?
FEMY does not pay a dividend.
How is the ChartMill rating for FEMASYS INC?
FEMY has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for FEMASYS INC?
FEMASYS INC (FEMY) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
Can you provide the growth outlook for FEMASYS INC?
The Revenue of FEMASYS INC (FEMY) is expected to decline by -2.37% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
FEMY Technical Analysis
FEMY Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to FEMY. FEMY may be in some trouble as it scores bad on both profitability and health.
FEMY Financial Highlights
Over the last trailing twelve months FEMY reported a non-GAAP Earnings per Share(EPS) of -0.71. The EPS increased by 12.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -121.55% | ||
| ROE | -434.59% | ||
| Debt/Equity | 1.43 |
FEMY Forecast & Estimates
9 analysts have analysed FEMY and the average price target is 5.27 USD. This implies a price increase of 792.47% is expected in the next year compared to the current price of 0.5905.
For the next year, analysts expect an EPS growth of 33.6% and a revenue growth -2.37% for FEMY